- A full cholesterol chart covers LDL, HDL, total and triglycerides, in both mmol/L and mg/dL.
- LDL is risk-stratified (<1.4 to <3.0 mmol/l); triglycerides <1.7 mmol/l.
- HDL: higher is better - but above ~2.3 mmol/l may paradoxically signal higher mortality risk.
- Women have higher HDL baselines than men (estrogen); a multi-pathway mushroom formula supports balance.
LDL cholesterol norm
LDL is the bad cholesterol. It especially needs to meet the norm, because it is the main factor helping your doctor work out the likelihood that you will have a circulatory event in the next 10 years. Important: the norms below are in mmol/L; if your results are in mg/dL, see the mg/dL norms. Choose your risk group to find your target.
| Risk group | LDL norm |
|---|---|
| Atherosclerosis, diabetes with organ damage, other very high risk | < 1.4 mmol/L |
| Diabetes >10 years, chronic kidney disease, BP ≥180/110 mmHg | < 1.8 mmol/L |
| Diabetes <10 years, type 2 diabetes | < 2.6 mmol/L |
| No risk group | < 3.0 mmol/L |
Triglycerides should be < 1.7 mmol/L (or < 2.3 mmol/L if tested after eating).
HDL cholesterol norm
HDL has a norm too, but the situation is reversed, because HDL is the good cholesterol — it helps lower the bad, so you want it as high as possible. Interestingly, if HDL exceeds 2.3 mmol/L, this may conversely indicate increased all-cause mortality risk, and scientists have not yet established why.2 General guidance: HDL above 1.0 mmol/L (men) and 1.2 mmol/L (women), preferably higher.
Total cholesterol norm
Total cholesterol is LDL and HDL combined. Below 5.0 mmol/L (about 200 mg/dL) is normal; 5–6 mmol/L is borderline; above 6 mmol/L is too high. However, the total figure alone is less informative than the LDL/HDL breakdown.
Cholesterol norm in mg/dL
If your results are reported in mg/dL: total below 200 mg/dL, LDL below 100 mg/dL (risk-adjusted lower), and HDL above 60 mg/dL is protective. To convert, multiply mmol/L by about 38.67.
Cholesterol and norms for women and men
Women usually have higher HDL than men because of estrogen, and levels shift across the menstrual cycle and rise after menopause. For men, HDL above 1.0 mmol/L is the baseline; for women, above 1.2 mmol/L. Otherwise the LDL and total targets are the same, adjusted for risk group.
What lowers cholesterol in the blood, so the level is good?
There are medicinal mushrooms whose compounds help lower LDL while supporting HDL, restoring the balance. A concentrated multi-extract formula is preferable to simple powders for cholesterol support.
Some mushroom compounds lower LDL while supporting HDL. A concentrated multi-extract formula is preferable to simple powders.
AURI 25 by Zenius Labs™ →Total cholesterol below 5.0 mmol/l. LDL ("bad") below 3.0 mmol/l (lower for higher-risk groups), and HDL ("good") above 1.0 mmol/l for men and 1.2 mmol/l for women. Triglycerides below 1.7 mmol/l. These ranges vary by age and risk factors.
Yes. For many people, adjusting diet, increasing physical activity, and taking quality mushroom-polysaccharide supplements is enough. A concentrated multi-extract formula such as AURI 25 by Zenius Labs™ is preferable to simple powders.
Yes — interestingly, if HDL exceeds about 2.3 mmol/l, this may conversely indicate an increased all-cause mortality risk, and the reason is not yet fully understood. For most people, higher HDL is protective.
To convert cholesterol from mmol/L to mg/dL, multiply by about 38.67 (e.g. 5.0 mmol/L ≈ 193 mg/dL). Total below 200 mg/dL, LDL below 100 mg/dL, HDL above 60 mg/dL is protective.
- PubMed 10856769. PubMed
- Yoon SJ et al. The nontoxic mushroom Auricularia auricula contains a polysaccharide with anticoagulant activity mediated by antithrombin. Thrombosis research. 2003. PubMed
- Bian C et al. A Novel Polysaccharide from AuriculariaAuricula Alleviates Thrombosis Induced by Carrageenan in Mice. Molecules (Basel, Switzerland). 2022. PubMed
- Shi Q et al. Isolation, Characterization, and Antioxidant Activity of Melanin from Auricularia auricula (Agaricomycetes). International journal of medicinal mushrooms. 2023. PubMed
- Yin CM et al. Physicochemical Properties and Antioxidant Activity of Natural Melanin Extracted from the Wild Wood Ear Mushroom, Auricularia auricula (Agaricomycetes). International journal of medicinal mushrooms. 2022. PubMed
- Liu X et al. Comprehensive utilization of edible mushroom Auricularia auricula waste residue-Extraction, physicochemical properties of melanin and its antioxidant activity. Food science & nutrition. 2019. PubMed
- González-Bonilla A et al. Dietary Supplementation with Oyster Culinary-Medicinal Mushroom, Pleurotus ostreatus (Agaricomycetes), Reduces Visceral Fat and Hyperlipidemia in Inhabitants of a Rural Community in Mexico. International journal of medicinal mushrooms. 2022. PubMed
- Abrams DI et al. Antihyperlipidemic effects of Pleurotus ostreatus (oyster mushrooms) in HIV-infected individuals taking antiretroviral therapy. BMC complementary and alternative medicine. 2011. PubMed
- Belobrajdic DP et al. β-Glucan content and in vitro bile-acid binding capacity of Agaricus bisporus and Pleurotus spp. Food & function. 2024. PubMed
- Maheshwari G et al. Characterization of the Nutritional Composition of a Biotechnologically Produced Oyster Mushroom and its Physiological Effects in Obese Zucker Rats. Molecular nutrition & food research. 2020. PubMed
- Sato M et al. Long-term intake of Tamogi-take mushroom (Pleurotus cornucopiae) mitigates age-related cardiovascular dysfunction and extends healthy life expectancy. npj aging. 2025. PubMed
- Gong J et al. Efficacy and safety of sugarcane policosanol on dyslipidemia: A meta-analysis of randomized controlled trials. Molecular nutrition & food research. 2018. PubMed
- Chen JT et al. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy. 2005. PubMed
- Millán J et al. Effects of a nutraceutical combination containing berberine (BRB), policosanol, and red yeast rice (RYR), on lipid profile in hypercholesterolemic patients: A meta-analysis of randomised controlled trials. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis. 2016. PubMed
- Singh DK et al. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. The Journal of pharmacology and experimental therapeutics. 2006. PubMed
- Castaño G et al. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus. Clinical drug investigation. 2003. PubMed
- Xiong Z et al. An overview of the bioactivity of monacolin K / lovastatin. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 2019. PubMed
- EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) et al. Scientific Opinion on additional scientific data related to the safety of monacolins from red yeast rice submitted pursuant to Article 8(4) of Regulation (EC) No 1925/2006. EFSA journal. European Food Safety Authority. 2025. PubMed
- Peng D et al. Original Research: The Effects of Red Yeast Rice Supplementation on Cholesterol Levels in Adults. The American journal of nursing. 2017. PubMed
- Gerards MC et al. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain – a systematic review and meta-analysis. Atherosclerosis. 2015. PubMed
- Cicero AFG et al. Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterolemia: A Narrative Review. Nutrients. 2023. PubMed
- Buzzelli L et al. Alternative lipid lowering strategies: State-of-the-art review of red yeast rice. Fitoterapia. 2024. PubMed
- Hermans MP et al. The antihyperlipidemic effect of a combined supplement of standardized dry extracts of amla (Emblica officinalis), walnut (Juglans regia), olive (Olea europaea) and red yeast rice (Monascus purpureus) powder: Reduction in circulatory low-density lipoprotein-cholesterol (LDL-C) and remnant cholesterol (RC) levels in patients with hypercholesterolemia. Frontiers in pharmacology. 2023. PubMed
- Sun HJ et al. Deficiency of neutral cholesterol ester hydrolase 1 (NCEH1) impairs endothelial function in diet-induced diabetic mice. Cardiovascular diabetology. 2024. PubMed
- Park C et al. Disturbed flow induces reprogramming of endothelial cells to immune-like and foam cells under hypercholesterolaemia during atherogenesis. Cardiovascular research. 2025. PubMed
- Zhang S et al. Natural products: The role and mechanism in low-density lipoprotein oxidation and atherosclerosis. Phytotherapy research : PTR. 2021. PubMed
- Wang J et al. DBZ (Danshensu Bingpian Zhi), a Novel Natural Compound Derivative, Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice. Journal of the American Heart Association. 2017. PubMed